Advertisement
For patients with pulmonary arterial hypertension

Selexipag Linked to Reduced Risk of Death, Complications in PAH

0
Reduced risk of composite of death or pulmonary arterial hypertension-linked complications
The U.S. Preventive Services Task Force (USPSTF) has found that current evidence is insufficient for determining the balance of benefits and harms of lipid disorder screening in children

Two Draft Statements From USPSTF Open for Comment

0
Insufficient evidence for lipid screening in children; recommendation for statins varies with age, risk
Uptravi (selexipag) has been approved by the U.S. Food and Drug Administration to treat adults with pulmonary arterial hypertension.

FDA Approves Uptravi for Pulmonary Arterial Hypertension

0
Drug found to limit worsening of the disease and reduce the need for hospitalization
Patients with sudden cardiac arrest frequently have warning symptoms

Many Ignore Warning Symptoms Before Sudden Cardiac Arrest

0
Survival significantly higher for patients who call emergency services in response to symptoms
In order to prevent denials

Specific, Consistent ICD-10 Coding Key to Timely Payments

0
Tips to prevent denials include checking EHR selection against documentation, being specific
Implementation of the Affordable Care Act has improved access to care and affordability of care for many adults

Affordable Care Act Has Improved Access to Care, Affordability

0
However, gaps in access to care and affordability still seen, especially for low-income adults
Better work environments and decreased patient-to-nurse ratios on medical-surgical units are associated with higher odds of patient survival after an in-hospital cardiac arrest

Nursing Conditions Tied to Hospital Cardiac Arrest Survival

0
Better work environments, decreased patient-to-nurse ratios up survival
The pepducin PZ-128 offers rapid

Pepducin PZ-128 Inhibits Platelet Protease-Activated Receptor-1

0
Rapid, specific, dose-dependent, reversible inhibition seen in patients with coronary artery disease
The use of transcatheter aortic-valve replacement increased in Germany from 2007 to 2013

Effect of Availability of TAVR on Clinical Practice Evaluated

0
Analysis of isolated TAVRs and surgical AV replacements performed in Germany 2007 to 2013
The LifeVest wearable defibrillator has been approved by the U.S. Food and Drug Administration for children at risk for cardiac arrest who can't have a defibrillator implanted. The device is already approved for adults.

FDA Approves LifeVest Wearable Defibrillator for Children

0
For heart patients who can't have device implanted